Biocardia Stock Performance
| BCDA Stock | USD 2.18 0.06 2.83% |
The firm shows a Beta (market volatility) of 1.03, which signifies a somewhat significant risk relative to the market. Biocardia returns are very sensitive to returns on the market. As the market goes up or down, Biocardia is expected to follow. At this point, Biocardia has a negative expected return of -0.2%. Please make sure to confirm Biocardia's skewness, rate of daily change, and the relationship between the value at risk and accumulation distribution , to decide if Biocardia performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Biocardia has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest unsteady performance, the Stock's fundamental indicators remain strong and the current disturbance on Wall Street may also be a sign of long term gains for the company investors. ...more
Actual Historical Performance (%)
One Day Return 1.87 | Five Day Return 4.81 | Year To Date Return (3.54) | Ten Year Return (98.78) | All Time Return (99.99) |
Last Split Factor 1:15 | Dividend Date 2019-06-06 | Last Split Date 2024-05-30 |
1 | Precision BioSciences Reports Q3 Loss, Misses Revenue Estimates | 11/04/2024 |
2 | Acquisition by Allen Jim L. of 12434 shares of Biocardia at 4.43 subject to Rule 16b-3 | 11/11/2024 |
3 | Femasys Inc. Reports Q3 Loss, Tops Revenue Estimates | 11/12/2024 |
4 | Acquisition by Peter Altman of 1350 shares of Biocardia at 1.87 subject to Rule 16b-3 | 11/15/2024 |
5 | BioCardia Announces Positive Consultation with Japan PMDA on CardiAMP Cell Therapy for Ischemic Heart Failure | 12/04/2024 |
6 | Acquisition by Peter Altman of 41666 shares of Biocardia at 3.0 subject to Rule 16b-3 | 12/09/2024 |
7 | BioCardia stock plunges to 52-week low of 1.81 amid market challenges - Investing.com | 12/19/2024 |
8 | Disposition of 3257 shares by Edward Gillis of Biocardia at 2.0 subject to Rule 16b-3 | 12/20/2024 |
9 | Acquisition by Peter Altman of 1000 shares of Biocardia at 2.06 subject to Rule 16b-3 | 12/23/2024 |
10 | Biocardia senior vice president Edward Gillis sells 6,514 in stock - Investing.com | 12/26/2024 |
11 | BioCardia, Inc. Short Interest Down .6 percent in December | 01/17/2025 |
| Begin Period Cash Flow | 7.4 M | |
| Free Cash Flow | -10 M |
Biocardia |
Biocardia Relative Risk vs. Return Landscape
If you would invest 268.00 in Biocardia on October 21, 2024 and sell it today you would lose (50.00) from holding Biocardia or give up 18.66% of portfolio value over 90 days. Biocardia is currently does not generate positive expected returns and assumes 5.2812% risk (volatility on return distribution) over the 90 days horizon. In different words, 47% of stocks are less volatile than Biocardia, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Biocardia Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Biocardia's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Biocardia, and traders can use it to determine the average amount a Biocardia's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.037
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | BCDA |
Estimated Market Risk
| 5.28 actual daily | 47 53% of assets are more volatile |
Expected Return
| -0.2 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.04 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Biocardia is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Biocardia by adding Biocardia to a well-diversified portfolio.
Biocardia Fundamentals Growth
Biocardia Stock prices reflect investors' perceptions of the future prospects and financial health of Biocardia, and Biocardia fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Biocardia Stock performance.
| Return On Equity | -7.04 | ||||
| Return On Asset | -1.16 | ||||
| Operating Margin | (549.67) % | ||||
| Current Valuation | 6.11 M | ||||
| Shares Outstanding | 4.58 M | ||||
| Price To Earning | (11.00) X | ||||
| Price To Book | 3.63 X | ||||
| Price To Sales | 23.35 X | ||||
| Revenue | 477 K | ||||
| Gross Profit | (4.64 M) | ||||
| EBITDA | (11.56 M) | ||||
| Net Income | (11.57 M) | ||||
| Cash And Equivalents | 8.61 M | ||||
| Cash Per Share | 0.49 X | ||||
| Total Debt | 1.31 M | ||||
| Debt To Equity | 0.26 % | ||||
| Current Ratio | 3.00 X | ||||
| Book Value Per Share | (1.02) X | ||||
| Cash Flow From Operations | (9.97 M) | ||||
| Earnings Per Share | (4.03) X | ||||
| Market Capitalization | 9.99 M | ||||
| Total Asset | 2.99 M | ||||
| Retained Earnings | (152.18 M) | ||||
| Working Capital | (2.15 M) | ||||
| Current Asset | 19.48 M | ||||
| Current Liabilities | 330 K | ||||
About Biocardia Performance
By analyzing Biocardia's fundamental ratios, stakeholders can gain valuable insights into Biocardia's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Biocardia has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Biocardia has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | (7.09) | (7.44) | |
| Return On Tangible Assets | (4.45) | (4.23) | |
| Return On Capital Employed | 16.88 | 17.72 | |
| Return On Assets | (4.45) | (4.23) | |
| Return On Equity | 6.50 | 6.82 |
Things to note about Biocardia performance evaluation
Checking the ongoing alerts about Biocardia for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Biocardia help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Biocardia generated a negative expected return over the last 90 days | |
| Biocardia has high historical volatility and very poor performance | |
| Biocardia has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 477 K. Net Loss for the year was (11.57 M) with loss before overhead, payroll, taxes, and interest of (4.64 M). | |
| Biocardia currently holds about 8.61 M in cash with (9.97 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.49. | |
| Roughly 14.0% of the company shares are held by company insiders | |
| Latest headline from thelincolnianonline.com: BioCardia, Inc. Short Interest Down .6 percent in December |
- Analyzing Biocardia's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Biocardia's stock is overvalued or undervalued compared to its peers.
- Examining Biocardia's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Biocardia's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Biocardia's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Biocardia's stock. These opinions can provide insight into Biocardia's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Biocardia Stock analysis
When running Biocardia's price analysis, check to measure Biocardia's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biocardia is operating at the current time. Most of Biocardia's value examination focuses on studying past and present price action to predict the probability of Biocardia's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biocardia's price. Additionally, you may evaluate how the addition of Biocardia to your portfolios can decrease your overall portfolio volatility.
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets |